The company has developed an innovative treatment that addresses the cause of the disease rather than the symptoms. The company has developed a patented molecule (AmyTrap) with demonstrated success in animal-model proof of concept studies to remove amyloid-beta, which is the physiological cause behind the plaque buildup in the brain associated with Alzheimer's Disease. Alzheimer's hits everybody hard; not just the sufferer who struggles with unimaginable frustration trying to remember the simplest of things; everyone around them feels pain and anguish watching someone close to them suffer. Recombinant Technologies has developed a unique treatment to a devastating medical problem to alleviate the anguish and bring relief.Continue Reading Recombinant Technologies has received multiple peer-reviewed grants (which in itself is a stamp of approval) from the National Institutes of Health to develop this Amytrapper devices.